Основная статистика
| LEI | 894500AHOYAGYLYZJL67 |
| CIK | 1403752 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zymeworks Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 14, 2023 |
ZYME / Zymeworks Inc / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G/A 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 01)* Zymeworks Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98985W102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2023 |
BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION EX-99 2 boa-poa2.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Kelvin Kwok, Tolu Tade, Andres Ortiz Custodio, Frank Lui, James Todd, Zainab Tarteel, Hannah Chae and Monica Yako as an attorney-in-fact for the Corporation acting for the Corporation and in the Corpora |
|
| February 6, 2023 |
ZYME / Zymeworks Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Zymeworks Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98985W102 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| October 24, 2022 |
tx15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38068 Zymeworks BC Inc.* (Exact name of registrant as specified |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2022 Zymeworks BC Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) |
|
| October 21, 2022 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM October 21, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Zymeworks Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), its common stock, par value $0.00001 pe |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Zymeworks BC Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) |
|
| October 19, 2022 |
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab Exhibit 99.2 Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab ? Jazz Pharmaceuticals to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan ? Zymeworks to receive $50 million upfront payment, a second payment of $325 million, at Jazz?s option, and further potential regulatory and commercial milestones for to |
|
| October 19, 2022 |
Exhibit 99.1 Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront payment, a second payment of $325 million, at Jazz?s option, and further poten |
|
| October 18, 2022 |
Exhibit 3.1 Date and Time: October 13, 2022 09:28 AM Pacific Time Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 Notice of Alteration FORM 11 BUSINESS CORPORATIONS ACT Section 257 Filed Date and Time: October 13, 2022 09:28 AM Pacific Time Alteration Date and Time: Notice of Articles |
|
| October 18, 2022 |
Exhibit 3.2 Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT T.K. SPARKS This Notice of Articles was issued by the Registrar on: October 13, 2022 |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 Zymeworks BC Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) |
|
| October 13, 2022 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 24, 2022, pursuant to the provisions of Rule 12d2-2 (a). |
|
| October 13, 2022 |
As filed with the Securities and Exchange Commission on October 13, 2022 As filed with the Securities and Exchange Commission on October 13, 2022 Registration No. |
|
| October 13, 2022 |
As filed with the Securities and Exchange Commission on October 13, 2022 As filed with the Securities and Exchange Commission on October 13, 2022 Registration No. |
|
| October 13, 2022 |
As filed with the Securities and Exchange Commission on October 13, 2022 As filed with the Securities and Exchange Commission on October 13, 2022 Registration No. |
|
| October 13, 2022 |
As filed with the Securities and Exchange Commission on October 13, 2022 As filed with the Securities and Exchange Commission on October 13, 2022 Registration No. |
|
| October 13, 2022 |
As filed with the Securities and Exchange Commission on October 13, 2022 S-8 POS 1 d369120ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 13, 2022 Registration No. 333-263042 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZYMEWORKS INC. (Exact name of registrant as specified in its charter) Delaware 88-3099146 (J |
|
| October 13, 2022 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 24, 2022, pursuant to the provisions of Rule 12d2-2 (a). |
|
| October 12, 2022 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| October 11, 2022 |
EX-99.1 Exhibit 99.1 ZYMEWORKS INC. (the “Company”) Special Meeting of Securityholders October 7, 2022 REPORT OF VOTING RESULTS Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations On October 7, 2022, the Company held a special meeting (the “Special Meeting”) of holders of: (i) common shares of the Company (each, a “Common Share” and the holders thereof, the “Zymeworks Sh |
|
| October 11, 2022 |
Zymeworks Announces Results of Special Meeting EX-99.2 Exhibit 99.2 Zymeworks Announces Results of Special Meeting VANCOUVER, British Columbia & SEATTLE – October 7, 2022 — Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce that the Company’s securityholders have approved its plan to become a Delaware corporation (the “Redomic |
|
| October 11, 2022 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| October 4, 2022 |
Zymeworks Reminds Shareholders to Vote FOR its Redomicile Exhibit 99.1 Zymeworks Reminds Shareholders to Vote FOR its Redomicile ? The Redomicile is anticipated to provide greater opportunities to enhance long-term value for securityholders, simplify commercialization efforts and monetization opportunities for our product candidates, and provide greater comparability to our peers. ? Leading independent proxy advisory firms, Institutional Shareholder Serv |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| October 3, 2022 |
Exhibit 99.1 Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day Vancouver, British Columbia and Seattle, Washington (October 03, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferen |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) ( |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) ( |
|
| September 26, 2022 |
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile Exhibit 99.1 Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile ? Institutional Shareholder Services joins Glass Lewis in recommending a vote FOR the Redomicile resolution ? ISS cites potential for improved capital raising ability and commercialization efficiencies for the Company?s lead product candidate, zanidatamab ? To vote, contact Kingsdale Advisors at 1-855-4 |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) ( |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) ( |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) ( |
|
| September 16, 2022 |
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile Exhibit 99.1 Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile ? Independent proxy advisory firm Glass Lewis recommends that Zymeworks shareholders vote FOR the Redomicile resolution ? Glass Lewis notes Zymeworks has made a compelling case that the Redomicile will favor the Company on the basis of more favorable corporate law ? To vote, contact Kings |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) ( |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) ( |
|
| September 12, 2022 |
Exhibit 99.1 Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress ? Company to hold conference call and webcast on Monday, September 12th at 4:30 PM Eastern Standard Time (EST) VANCOUVER, British Columbia & SEATTLE - SEPTEMBER 12, 2022?Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company dev |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (C |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (C |
|
| September 8, 2022 |
Exhibit 99.1 Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware ? Redomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better position the Company for future growth ? Zymeworks Board recommends that Zymeworks securityholders vote FOR the Redomicile |
|
| September 6, 2022 |
Exhibit 99.1 Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers ? Zanidatamab zovodotin shown to have manageable safety profile with encouraging, single-agent anti-tumor activity in patients with HER2+ cancers ? Results to be reviewed in an oral presentation at European Society for Medical Oncology (ESMO) Congress 2022 in Paris Monday, S |
|
| September 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (C |
|
| September 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (C |
|
| September 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| September 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (C |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| August 19, 2022 |
Exhibit 2.1 RESTATED AND AMENDED TRANSACTION AGREEMENT BY AND AMONG ZYMEWORKS DELAWARE INC. ZYMEWORKS CALLCO ULC ZYMEWORKS EXCHANGECO LTD. AND ZYMEWORKS INC. DATED AS OF AUGUST 18, 2022 B-1 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION B-5 1.1 Original Agreement B-5 1.2 Defined Terms B-5 1.3 Headings and References B-9 1.4 Time Periods B-9 1.5 Currency B-9 1.6 Time B-10 1.7 Construction B-10 1.8 Gove |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-38068 (Commission Fil |
|
| August 8, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock of Zymeworks Inc., which may be deemed necessary pursu |
|
| August 8, 2022 |
ZYME / Zymeworks Inc / Redmile Group, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Zymeworks Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98985W102 (CUSIP Number) July 29, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| August 5, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Zymeworks Inc. (?Zymeworks? or the ?Company?) 114 East 4th Avenue?Suite 800 Vancouver, BC, Canada V5T 1G4 Item 2: Date of Material Change August 4, 2022 Item 3: News Release A news release announcing the material change was disseminated through the facilities of Business Wire on August 4, 2022, and a copy was fil |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Comm |
|
| August 4, 2022 |
TABLE OF CONTENTS BUSINESS CORPORATIONS ACT ARTICLES of ZYMEWORKS INC. Pafie 3.1 3.2 51021069.7 4.1 4.2 5.1 5.2 5.3 5.4 1.1 1.2 Central Securities Register Closing Register ARTICLE 5 SHARE TRANSFERS ARTICLE 3 ISSUE OF SHARES 1 1 Definitions Business Corporations Act and Interpretation Act Definitions Applicable Registering Transfers Form of Instrument of Transfer.... Transferor Remains Shareholder |
|
| August 4, 2022 |
Exhibit 10.4 EMPLOYMENT AGREEMENT THIS AGREEMENT is made and effective as of July 18, 2022 (the ?Effective Date?). BETWEEN: PAUL MOORE, an individual having a residence at [?***?]1. (the ?Employee?), on the one hand AND, on the other hand: ZYMEWORKS BIOPHARMACEUTICALS INC., a corporation registered in the State of Washington and having its principal place of business at 2100-1215 Fourth Avenue, Se |
|
| August 4, 2022 |
Exhibit 10.2 NOTICE OF ASSIGNMENT OF LEASE DATE: January 1, 2022 TO: Zymeworks Inc. (the "Tenant") FROM: 5th & Main Partnership (the "Assignor"); 2000 Main Holdings Inc. and Mount Pixel Projects Limited Partnership (together, the "Interim Owner"); and 130 E 4th Partnership (the "Assignee") RE: Lease dated for reference January 25, 2019, as amended and modified from time to time (collectively, the |
|
| August 4, 2022 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK ?[?***?]?. CONFIDENTIAL EXECUTION COPY THIRD AMENDMENT TO COLLABORATION AND CROS |
|
| August 4, 2022 |
Exhibit 10.1 LEASE AMENDING AGREEMENT THIS AGREEMENT dated for reference April 1, 2022, BETWEEN: 130 E 4TH PARTNERSHIP (the "Landlord") AND: ZYMEWORKS INC. (the "Tenant") WITNESSES THAT WHEREAS: A.Pursuant to a lease dated for reference January 25, 2019 (the "Original Lease") between 5th & Main Partnership (the "Original Landlord"), as landlord, and the Tenant, as tenant, the Original Landlord lea |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 4, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Comm |
|
| August 4, 2022 |
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results ?Zanidatamab zovodotin (ZW49) accepted for oral presentation of Phase 1 clinical data at European Society for Medical Oncology (ESMO) Congress in September ?Announced Early Research and Development (eR&D) day presentation and webcast for October 20th, 2022 with focus on TOPO1i antibody-drug conjugate and multi-sp |
|
| August 4, 2022 |
Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 Notice of Articles BUSINESS CORPORATIONS ACT CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies T.K. SPARKS This Notice of Articles was issued by the Registrar on: June 10, 2022 01:32 PM Pacif |
|
| August 2, 2022 |
Zymeworks Announces Participation in Upcoming Investor Conferences Exhibit 99.1 Zymeworks Announces Participation in Upcoming Investor Conferences Vancouver, British Columbia and Seattle, Washington (August 1, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: ? Citi?s 17th Annual BioPharma C |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Comm |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commi |
|
| July 25, 2022 |
Exhibit 99.1 Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris • Oral presentation will take place on Monday, September 12 at 5:25 pm Central European Summer Time (CEST) VANCOUVER, British Columbia & SEATTLE—(BUSINESS WIRE)—July 25, 2022 — Zymeworks Inc. (NYSE: ZYM |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commi |
|
| July 22, 2022 |
Zymeworks Reports Inducement Grant to New Chief Scientific Officer Exhibit 99.1 Zymeworks Reports Inducement Grant to New Chief Scientific Officer Vancouver, Canada and Seattle, Washington (July 22, 2022) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE Rule”), an equity inducement award to D |
|
| July 21, 2022 |
Zymeworks to Host Second Quarter Results Conference Call Exhibit 99.1 Zymeworks to Host Second Quarter Results Conference Call Vancouver, Canada and Seattle, Washington (July 21, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results after market close on August 4th, 2022. Following the announcement, |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commi |
|
| July 15, 2022 |
EX-99.1 3 d373368dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Announces Plan to Become a Delaware Corporation • Enhances alignment with US shareholder base and other peer biotechnology companies • Positions company for growth while helping to reduce complexity and certain administrative costs • The Company’s name, brand, and ticker symbol to remain unchanged Vancouver, Canada and Seattle, Washington |
|
| July 15, 2022 |
Filed by Zymeworks Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymeworks Inc. Commission File: 001-38068 On July 15, 2022, Zymeworks Inc. made the following materials available to employees. Redomicile On July 15, we issued a press release announcing our plans to become a Delaware Cor |
|
| July 15, 2022 |
Filed by Zymeworks Delaware Inc. 425 1 d346220d425.htm 425 Filed by Zymeworks Delaware Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymeworks Inc. Commission File No. for Registration Statement on Form S-4 filed by Zymeworks Delaware Inc.: 333-266160 On July 15, 2022, Kenneth Galbraith, Chair and CEO of Zymeworks Inc. |
|
| July 15, 2022 |
EX-2.1 2 d373368dex21.htm EX-2.1 Exhibit 2.1 TRANSACTION AGREEMENT BY AND AMONG ZYMEWORKS DELAWARE INC. ZYMEWORKS CALLCO ULC ZYMEWORKS EXCHANGECO LTD. AND ZYMEWORKS INC. DATED AS OF July 14, 2022 1 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 5 1.1 Defined Terms 5 1.2 Headings and References 9 1.3 Time Periods 9 1.4 Currency 9 1.5 Time 10 1.6 Construction 10 1.7 Governing Law 10 ARTICLE 2 THE ARRANG |
|
| July 15, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.2 4 d373368dex992.htm EX-99.2 Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Zymeworks Inc. (“Zymeworks” or the “Company”) 114 East 4th Avenue - Suite 800 Vancouver, BC, Canada V5T 1G4 Item 2: Date of Material Change July 14, 2022 Item 3: News Release A news release announcing the material change was disseminated through the facilities of Business Wire |
|
| July 15, 2022 |
Filed by Zymeworks Delaware Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymeworks Inc. Commission File No. for Registration Statement on Form S-4 filed by Zymeworks Delaware Inc.: 333-266160 On July 15, 2022, Zymeworks Inc. made available to investors and the public a pre-recorded web |
|
| July 15, 2022 |
Filed by Zymeworks Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymeworks Inc. Commission File: 001-38068 On July 15, 2022, Kenneth Galbraith, Chair and CEO of Zymeworks Inc. (the ?Company?), sent the following email to employees of the Company. Everyone, Today ahead of market open we |
|
| July 15, 2022 |
Filed by Zymeworks Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymeworks Inc. Commission File: 001-38068 On July 15, 2022, Zymeworks Inc. made available to investors and the public a pre-recorded webcast presentation. The transcript of the presentation is included below, and the slide |
|
| July 15, 2022 |
Filed by Zymeworks Delaware Inc. Filed by Zymeworks Delaware Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymeworks Inc. Commission File No. for Registration Statement on Form S-4 filed by Zymeworks Delaware Inc.: 333-266160 On July 15, 2022, Zymeworks Inc. made the following materials available to employees. Redomici |
|
| July 15, 2022 |
Filed by Zymeworks Delaware Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymeworks Inc. Commission File No. for Registration Statement on Form S-4 filed by Zymeworks Delaware Inc.: 333-266160 On July 15, 2022, Zymeworks Inc. issued the following press release. Zymeworks Announces Plan |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commi |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commi |
|
| July 15, 2022 |
Filed by Zymeworks Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymeworks Inc. Commission File: 001-38068 On July 15, 2022, Zymeworks Inc. made available to investors and the public a pre-recorded webcast presentation. The slides used in the presentation are reproduced below, and the t |
|
| July 15, 2022 |
Filed by Zymeworks Delaware Inc. Filed by Zymeworks Delaware Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymeworks Inc. Commission File No. for Registration Statement on Form S-4 filed by Zymeworks Delaware Inc.: 333-266160 On July 15, 2022, Zymeworks Inc. made available to investors and the public a pre-recorded web |
|
| June 27, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Zymeworks Inc. (?Zymeworks? or the ?Company?) 114 East 4th Avenue?Suite 800 Vancouver, BC, Canada V5T 1G4 Item 2: Date of Material Change June 27, 2022 Item 3: News Release A news release announcing the material change was disseminated through the facilities of Business Wire on June 27, 2022, and a copy was filed |
|
| June 27, 2022 |
Exhibit 99.1 Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer Dr. Moore will lead Zymeworks? Early Research & Development Group responsible for advancing the Company?s next-generation of multispecific antibody programs and antibody drug conjugate (ADC) programs into clinical studies Vancouver, Canada and Seattle, Washington (June 27, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-sta |
|
| June 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commi |
|
| June 10, 2022 |
Exhibit 99.1 Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company ? Plan ensures shareholders are protected and treated equitably ? Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders Vancouver, Canada and Seattle, Washington (June 10, 2022) ? Zymeworks I |
|
| June 10, 2022 |
EX-4.1 2 d319186dex41.htm EX-4.1 Exhibit 4.1 PREFERRED SHARES RIGHTS AGREEMENT Dated as of June 9, 2022 between ZYMEWORKS INC. and COMPUTERSHARE TRUST COMPANY, N.A., as Rights Agent TABLE OF CONTENTS Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 12 Section 3. Issuance of Rights Certificates 12 Section 4. Form of Rights Certificates 14 Section 5. Countersignature and |
|
| June 10, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.2 4 d319186dex992.htm EX-99.2 Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Zymeworks Inc. (“Zymeworks” or the “Company”) 114 East 4th Avenue - Suite 800 Vancouver, BC, Canada V5T 1G4 Item 2: Date of Material Change June 9, 2022 Item 3: News Release A news release announcing the material change was disseminated through the facilities of Business Wire o |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commis |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1398788 (State of incorporation or organization) (I.R.S. Employer Identification No.) Suite 800, 11 |
|
| May 27, 2022 |
Zymeworks Announces Participation in Upcoming Investor Conference Exhibit 99.1 Zymeworks Announces Participation in Upcoming Investor Conference Vancouver, Canada and Seattle, Washington (May 27, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: ? Jefferies Healthcare Conference. Zymeworks |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commis |
|
| May 26, 2022 |
ZYME / Zymeworks Inc / All Blue Falcons FZE - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Zymeworks Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98985W102 (CUSIP Number of Class of Securities) Daniel Cookson All Blue Falcons FZE Office 2301 23rd Floor API Trio Tower Al Barsha 1 Dubai, United Arab |
|
| May 26, 2022 |
Exhibit 99.1 Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2-Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022 ? Study of zanidatamab in combination with docetaxel results in 90.5% confirmed objective response rate (cORR) in first-line treatment of advanced HER2-positive breast cancer ? Zanidatamab in combination with chemothe |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commis |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commis |
|
| May 20, 2022 |
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal EX-99.1 2 d244477dex991.htm EX-99.1 Exhibit 99.1 Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal • Opportunistic proposal from activist shareholder substantially undervalues Zymeworks and is not in the best interests of shareholders • Shareholders are right to question the motive behind an activist proposal that was concurrently released to the media and sent to |
|
| May 20, 2022 |
EX-99.3 2 tm2216134d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC. Siddhartha Mukherjee, MD, Hematology and Oncology Medical Expert, Rhodes Scholar and Pulitzer Prize Winning Author, Recently Joined All Blue as Medical Advisor All Blue Urges Zymeworks Board to Engage with All Blue on Its Compelling $10.50 Per Sha |
|
| May 20, 2022 |
ZYME / Zymeworks Inc / All Blue Falcons FZE - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Zymeworks Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98985W102 (CUSIP Number of Class of Securities) Daniel Cookson All Blue Falcons FZE Office 2301 23rd Floor API Trio Tower Al Barsha 1 Dubai, United Arab |
|
| May 4, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commiss |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 4, 2022 |
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results EX-99.1 2 exhibit991q12022xpressxre.htm EX-99.1 Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results •Last patient enrolled ahead of expectations in pivotal trial evaluating zanidatamab as monotherapy in 2L biliary tract cancers (BTC) •Two zanidatamab data presentations at ASCO in June: 1L breast cancer and 1L gastroesophageal adenocarcinoma (GEA) •Presented topoiso |
|
| May 2, 2022 |
EX-10.70 4 d357655dex1070.htm EX-10.70 Exhibit 10.70 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Kathryn O’Driscoll (“Employee”) and Zymeworks Biopharmaceuticals Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee was employed at-will by the Company; WHEREAS, Emp |
|
| May 2, 2022 |
Zymeworks Announces Participation in Upcoming Investor Conferences EX-99.1 2 d260432dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Announces Participation in Upcoming Investor Conferences Vancouver, Canada and Seattle, Washington (May 02, 2022) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: • H.C. W |
|
| May 2, 2022 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2022 (Original Report) April 28, 2022 (Amended Report) Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-139878 |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commiss |
|
| May 2, 2022 |
Notice of Articles of the Company. EX-3.1 2 d357655dex31.htm EX-3.1 Exhibit 3.1 Mailing Address: Location: PO Box 9431 Stn Prov Govt 2nd Floor - 940 Blanshard Street Victoria BC V8W 9V3 Victoria BC www.corporateonline.gov.bc.ca 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT CAROL PREST This Notice of Articles was issued by t |
|
| May 2, 2022 |
EX-10.69 3 d357655dex1069.htm EX-10.69 Exhibit 10.69 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Anthony Polverino (“Employee”) and Zymeworks Biopharmaceuticals Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee was employed at-will by the Company; WHEREAS, Empl |
|
| May 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission f |
|
| April 29, 2022 |
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons EX-99.1 2 d266209dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons Vancouver, Canada and Seattle, Washington (April 28, 2022) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today confirmed it has received an unsolicited, non-binding proposal fro |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Comm |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Comm |
|
| April 28, 2022 |
Exhibit 99.1 Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer Vancouver, Canada and Seattle, Washington (April 28, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it has completed enrollment in its glo |
|
| April 28, 2022 |
ZYME / Zymeworks Inc / All Blue Falcons FZE - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zymeworks Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98985W102 (CUSIP Number of Class of Securities) Daniel Cookson All Blue Falcons FZE Office 2301 23rd Floor API Trio Tower Al Barsha 1 Dubai, United Arab |
|
| April 28, 2022 |
Exhibit 99.2 Office 2301 API Trio Tower Al Barsha, Dubai, United Arab Emirates Email: [email protected] Tel: +44 7502 018701 VIA EMAIL AND HAND DELIVERY April 28, 2022 Board of Directors Zymeworks Inc. 540-1385 West 8th Avenue Vancouver, BC V6H 3V9 Dear Members of the Board of Directors: On behalf of All Blue Falcons FZE (?All Blue?), and its respective affiliated investment funds that, di |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Comm |
|
| April 27, 2022 |
Exhibit 99.1 Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Vancouver, Canada and Seattle, Washington (April 27, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, in conjunction with its Asia Pacific partner BeiGene, the acceptance of two abstracts for p |
|
| April 22, 2022 |
ZYME / Zymeworks Inc / All Blue Falcons FZE - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Zymeworks Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98985W102 (CUSIP Number of Class of Securities) Daniel Cookson All Blue Falcons FZE Office 2301 23rd Floor API Trio Tower Al Barsha 1 Dubai, United Arab |
|
| April 22, 2022 |
99.1 Joint Filing Agreement, dated as of April 22, 2022, by and among the Reporting Persons. EX-99.1 2 tm2213368d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) THIS JOINT FILING AGREEMENT is entered into as April 22, 2022, by and among the parties hereto. The undersigned hereby agree that the Statement on Schedule 13D with respect to the common shares, no par value, of Zymeworks Inc. and any amendment thereafter signed by each of the undersigned |
|
| April 19, 2022 |
Zymeworks to Host First Quarter 2022 Results Conference Call Exhibit 99.1 Zymeworks to Host First Quarter 2022 Results Conference Call Vancouver, Canada and Seattle, Washington (April 19, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its first quarter 2022 financial results after market close on May 4th, 2022. Following the announcement, |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Comm |
|
| April 1, 2022 |
Zymeworks Announces Participation in Upcoming Investor Conferences Exhibit 99.1 Zymeworks Announces Participation in Upcoming Investor Conferences Vancouver, Canada and Seattle, Washington (April 01, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences: ? Wells Fargo 2022 Biotech Forum. Zymeworks |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commi |
|
| March 9, 2022 |
EX-10.1 2 d497055dex101.htm EX-10.1 Exhibit 10.1 ZYMEWORKS INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1 “Actual Award” means as to any Performance Period, the actu |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commi |
|
| March 3, 2022 |
Zymeworks Announces Participation in Upcoming Investor Conferences Exhibit 99.1 Zymeworks Announces Participation in Upcoming Investor Conferences Vancouver, Canada and Seattle, Washington (March 03, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences during March: ? Barclays Global Healthcare Co |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commi |
|
| February 25, 2022 |
Power of Attorney (included on page II-5 of this Registration Statement). As filed with the Securities and Exchange Commission on February 25, 2022 Registration No. |
|
| February 25, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Zymeworks Inc. (Exact name of registrant as specified in its charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value per |
|
| February 25, 2022 |
As filed with the Securities and Exchange Commission on February 25, 2022 As filed with the Securities and Exchange Commission on February 25, 2022 Registration No. |
|
| February 25, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Zymeworks Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value per |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (C |
|
| February 25, 2022 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT is made and effective as of February 24, 2022 (the ?Effective Date?). BETWEEN: Dr. Christopher Astle, having a residence at [?***?]1 (the ?Employee?) AND: ZYMEWORKS INC., a corporation registered in the Province of British Columbia and having its principal place of business at 800-114 East 4th Avenue, Vancouver, BC, V5T 1G4, Can |
|
| February 25, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.1 3 d295460dex991.htm EX-99.1 Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Zymeworks Inc. (“Zymeworks” or the “Company”) 114 East 4th Avenue - Suite 800 Vancouver, BC, Canada V5T 1G4 Item 2: Date of Material Change February 24, 2022 Item 3: News Release A news release announcing the material change was disseminated through the facilities of Business W |
|
| February 24, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (C |
|
| February 24, 2022 |
Notice of Articles of the Registrant. Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 Notice of Articles BUSINESS CORPORATIONS ACT CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies CAROL PREST This Notice of Articles was issued by the Registrar on: January 26, 2022 11:16 AM Pa |
|
| February 24, 2022 |
EX-10.63 4 zyme-20211231xex1063.htm EX-10.63 Exhibit 10.63 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between James Priour (“Employee”) and Zymeworks Biopharmaceuticals Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee was employed at-will by the Company; WHEREAS, Emp |
|
| February 24, 2022 |
Exhibit 10.66 9 November 2021 Mr. Neil Josephson Interim Chief Medical Officer Promotion to Chief Medical Officer Dear Neil, On behalf of the Board of Directors of Zymeworks Inc. (?Zymeworks?), I am pleased to confirm your promotion to the position of Chief Medical Officer, effective 15 November 2021, and the following changes to your compensation: Current New Base Salary (USD) $453,200 $480,000 B |
|
| February 24, 2022 |
EX-4.1 3 a41specimencommonsharece.htm EX-4.1 A COMPANY INCORPORATED UNDER THE LAWS OF BRITISH COLUMBIA SEE REVERSE FOR CERTAIN DEFINITIONS in the Authorized share structure of the above named Company subject to the Articles of the Company transferable on the Central Securities Register of the Company by the registered holder in person or by attorney duly authorized in writing upon surrender of thi |
|
| February 24, 2022 |
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results ?Enrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). |
|
| February 24, 2022 |
Exhibit 21.1 Subsidiaries of the Company As of December 31, 2021 Name of Subsidiary State of Incorporation Zymeworks Biopharmaceuticals Inc. Washington |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| February 15, 2022 |
ZYME / Zymeworks Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Zymeworks Inc.. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98985W 102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 15, 2022 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2022 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2022 |
ZYME / Zymeworks Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zymeworks Inc. (Name of Issuer ? as specified in its charter) Common Shares, no par value per share (Title of Class of Securities) 98985W102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
EX-99.1 2 ex991.htm EX-99.1 In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets |
|
| February 14, 2022 |
ZYME / Zymeworks Inc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
ZYME / Zymeworks Inc / CREDIT SUISSE AG/ - NONE Passive Investment SC 13G 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Zymeworks Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98985W102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 10, 2022 |
ZYME / Zymeworks Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 ZYMESC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ZYMEWORKS INC. (Name of Issuer) COMMON SHARES, NO PAR VALUE PER SHARE (Title of Class of Securities) 98985W102 (CUSIP Number) FEBRUARY 2, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| February 8, 2022 |
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call EX-99.1 2 d244869dex991.htm EX-99.1 Exhibit 99.1 Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call Vancouver, Canada and Seattle, Washington (February 08, 2022) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 financial res |
|
| February 4, 2022 |
ZYME / Zymeworks Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zymeworks Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98985W102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 3, 2022 |
Zymeworks Announces Participation in Upcoming Investor Conferences EX-99.1 2 d304104dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Announces Participation in Upcoming Investor Conferences Vancouver, Canada and Seattle, Washington (February 03, 2022) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences. • Guggenheim Oncology |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| January 31, 2022 |
ZYME / Zymeworks Inc / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Zymeworks Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98985W102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 31, 2022 |
Exhibit 99.1 Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters? Option to Purchase Additional Shares Vancouver, Canada and Seattle, Washington (January 31, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the closing of its previously announced underwritten public offeri |
|
| January 31, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Zymeworks Inc. (?Zymeworks? or the ?Company?) 1385 West 8th Avenue, Suite 540 Vancouver, BC, Canada V6H 3V9 Item 2: Date of Material Change January 26, 2022 and January 31, 2022 Item 3: News Release News releases dated January 26, 2022 and January 31, 2022 were disseminated through the facilities of Business Wire |
|
| January 27, 2022 |
Zymeworks Announces Pricing of $100.0 Million Public Offering Exhibit 99.2 Zymeworks Announces Pricing of $100.0 Million Public Offering Vancouver, Canada and Seattle, Washington (January 26, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the pricing of its underwritten public offering of 9,160,000 common shares and, in lieu of common shares to certain investors, pre |
|
| January 27, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259970 CALCULATION OF REGISTRATION FEE Title Of Each Class of Securities to be Registered Number of Securities to be Registered Maximum Offering Price Per Security Maximum Aggregate Offering Price Amount of Registration Fee Common Shares, no par value 14,375,000(1) $8.00 $115,000,000.00 $10,660.50 Pre-Funded Warrants to Purcha |
|
| January 27, 2022 |
Underwriting Agreement dated January 26, 2022 EX-1.1 2 d302094dex11.htm EX-1.1 Exhibit 1.1 Zymeworks Inc. 9,160,000 Common Shares and Pre-Funded Warrants to Purchase 3,340,000 Common Shares Underwriting Agreement New York, New York January 26, 2022 Jefferies LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Street, 35th |
|
| January 27, 2022 |
EX-4.1 3 d302094dex41.htm EX-4.1 Exhibit 4.1 [FORM OF PRE-FUNDED] WARRANT TO PURCHASE COMMON SHARES Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ] Zymeworks Inc., a company continued under the Business Corporations Act (British Columbia) (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby a |
|
| January 27, 2022 |
Zymeworks Announces Proposed Public Offering EX-99.1 5 d302094dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Announces Proposed Public Offering Vancouver, Canada and Seattle, Washington (January 26, 2022) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to cer |
|
| January 27, 2022 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| January 26, 2022 |
SUBJECT TO COMPLETION, DATED JANUARY 26, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259970 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying |
|
| January 19, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.2 3 d461277dex992.htm EX-99.2 Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Zymeworks Inc. (“Zymeworks” or the “Company”) 1385 West 8th Avenue, Suite 540 Vancouver, BC, Canada V6H 3V9 Item 2: Date of Material Change January 19, 2022 Item 3: News Release A news release announcing the material change was disseminated through the facilities of Business Wi |
|
| January 19, 2022 |
Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| January 19, 2022 |
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022 EX-99.1 2 d461277dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022 • New Chair and CEO, Mr. Kenneth Galbraith, outlines strategic priorities for 2022 and 2023 across key clinical development activities for zanidatamab and ZW49, preclinical R&D pipeline, collaborations and partnerships • Further changes to leadership team announced |
|
| January 18, 2022 |
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule Exhibit 99.1 Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule Vancouver, Canada and Seattle, Washington (January 15, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the ?NYSE Rule?), an |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| January 6, 2022 |
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference Exhibit 99.1 Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference Vancouver, Canada and Seattle, Washington (January 6, 2022) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Klompas, Zymeworks? Chief Operating Officer and Chief Financial Officer, will present at the upcoming 40th Annual |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| January 5, 2022 |
Exhibit 10.3 5 January 2022 Mr. Neil Klompas Executive Vice President, Business Operations and Chief Financial Officer Promotion to Chief Operating Officer Dear Neil, On behalf of the Board of Directors of Zymeworks Inc. (?Zymeworks?), I am pleased to confirm your promotion to the position of Chief Operating Officer, effective 5 January 2022 (you will remain as Chief Financial Officer as well), an |
|
| January 5, 2022 |
Exhibit 10.4 ZYMEWORKS INC. INDUCEMENT STOCK OPTION AND EQUITY COMPENSATION PLAN TABLE OF CONTENTS ARTICLE I INTERPRETATION 1 Section 1.1 Definitions 1 Section 1.2 Interpretation 5 ARTICLE II GENERAL PROVISIONS 5 Section 2.1 Administration 5 Section 2.2 Shares Reserved 6 Section 2.3 Amendment and Termination 7 Section 2.4 Compliance with Legislation 8 Section 2.5 Effective Time and Termination 8 S |
|
| January 5, 2022 |
EX-99.1 6 d207208dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani • Co-founder Dr. Ali Tehrani to remain as an advisor to the Company to assist in the transition expected to occur on or before February 1, 2022 • Chief Financial Officer (CFO) Neil Klompas also promoted to the dual position of Chief Operating |
|
| January 5, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Zymeworks Inc. (?Zymeworks? or the ?Company?) 1385 West 8th Avenue, Suite 540 Vancouver, BC, Canada V6H 3V9 Item 2: Date of Material Change January 5, 2022 Item 3: News Release A news release announcing the material change was disseminated through the facilities of Business Wire on January 5, 2022 and a copy was |
|
| January 5, 2022 |
EX-10.2 3 d207208dex102.htm EX-10.2 Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE THIS SEPARATION AGREEMENT AND RELEASE is made on January 5, 2022. BETWEEN: ZYMEWORKS INC. (“Zymeworks” or the “Company”) AND: DR. ALI TEHRANI (the “Executive”) WHEREAS: A. The Executive was employed by Zymeworks since September 8, 2003, pursuant to an amended and restated employment agreement dated January 17, 2017 ( |
|
| January 5, 2022 |
EX-10.1 2 d207208dex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT is made and effective as of the date the Employee commences employment with the Company, which date is expected to be on or before February 1, 2022 (the actual first day of employment with the Company, the “Effective Date”, BETWEEN: Mr. Kenneth Galbraith, having a residence at Corners, Moules Lane, Hadstock, Cambr |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| December 9, 2021 |
EX-99.1 2 d260676dex991.htm EX-99.1 Exhibit 99.1 Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer • Overall confirmed objective response rate (cORR) of 36.4% and disease control rate (DCR) of 86.4% • Median progression-free survival (mPFS) of 7.3 months overall • |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| December 9, 2021 |
EX-99.1 2 d10637dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment • First patient dosed in South Korea under Zymeworks and BeiGene collaboration agreement • HERIZON-GEA-01 enrollment progresses with multiple active sites and continued global recruitment • Zymeworks to receive US$8MM deve |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| December 1, 2021 |
Exhibit 99.1 Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric? and EFECT? Therapeutic Platforms Vancouver, Canada (December 1, 2021) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Janssen Biotech, Inc. (?Janssen?) dosed the first patient with JNJ-78306 |
|
| November 19, 2021 |
EX-99.1 2 d208558dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS) • Full presentation available December 8 at 5:00 pm Central Time (CT) Vancouver, Canada (November 19, 2021) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (C |
|
| November 9, 2021 |
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer EX-99.2 3 d217459dex992.htm EX-99.2 Exhibit 99.2 Zymeworks Names Neil Josephson, M.D., Chief Medical Officer Vancouver, British Columbia (November 9, 2021) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Josephson, M.D., who has been serving as the company’s interim Chief Medical Officer (CMO) since May |
|
| November 9, 2021 |
EX-99.1 2 d217459dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) • HERIZON-GEA-01 study is now open and enrolling patients to evaluate zanidatamab and chemotherapy with or without tislelizumab, versus standard of care • Phase 2 data demonstrate potential benefit of zanidatamab in first-line GEA, w |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2021 |
Zymeworks to Present at Upcoming Investor Conferences Exhibit 99.1 Zymeworks to Present at Upcoming Investor Conferences Vancouver, British Columbia (November 08, 2021) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming investor conferences. ? Stifel 2021 Virtual Healthcare Conference, November 16th ? 17th. Zymeworks i |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 3, 2021 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. |
|
| November 3, 2021 |
EX-99.1 6 zyme-20210930xex991.htm EX-99.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[…***…]”. CONFIDENTIAL FOURTH AMENDMENT TO COLLABO |
|
| November 3, 2021 |
Zymeworks Reports 2021 Third Quarter Financial Results Zymeworks Reports 2021 Third Quarter Financial Results Vancouver, Canada (November 3, 2021) ? Zymeworks Inc. |
|
| November 3, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| October 26, 2021 |
EX-99.1 2 d247827dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers Vancouver, British Columbia (October 26, 2021) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will host a con |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Co |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| October 5, 2021 |
EX-99.1 2 d204577dex991.htm EX-99.1 Exhibit 99.1 Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors Vancouver, Canada and South San Francisco, California (October 5, 2021) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company de |
|
| October 1, 2021 |
EX-1.1 2 d237389dex11.htm EX-1.1 Exhibit 1.1 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM October 1, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (this “Amendment”) is entered into as of the date first written above by Zymeworks Inc., a corporation continued under the Business Corporations Act ( |
|
| October 1, 2021 |
As filed with the Securities and Exchange Commission on October 1, 2021 Table of Contents As filed with the Securities and Exchange Commission on October 1, 2021 Registration No. |
|
| October 1, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259970 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Proposed maximum aggregate offering price Amount of registration fee(1) Common Shares, no par value $150,000,000 $13,905(2) (1) Calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended, or the Securities Act, |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Com |
|
| October 1, 2021 |
Exhibit 4.4 ZYMEWORKS INC. INDENTURE Dated as of Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment of Terms of Series o |
|
| September 16, 2021 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.2 3 d195420dex992.htm EX-99.2 Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Zymeworks Inc. (“Zymeworks” or the “Company”) 1385 West 8th Avenue, Suite 540 Vancouver, BC, Canada V6H 3V9 Item 2: Date of Material Change September 16, 2021 Item 3: News Release A news release announcing the material change was disseminated through the facilities of Business |
|
| September 16, 2021 |
Exhibit 99.1 Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress ? Confirmed objective response rate (cORR) of 75% overall and 93% for the proposed Phase 3 regimen (zanidatamab + CAPOX/FP) ? Median duration of response (mDOR) of 16 |
|
| September 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) ( |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) ( |
|
| September 13, 2021 |
EX-99.1 2 d202904dex991.htm EX-99.1 Exhibit 99.1 Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress • Abstract data demonstrate encouraging antitumor activity in first-line GEA • Full ESMO presentation available September 16 at 8:30 am CEST, 2:30 am ET • Conference call and we |
|
| August 4, 2021 |
EX-99.5 12 zyme-20210630xex995.htm EX-99.5 Exhibit 99.5 FOURTH LEASE MODIFICATION AGREEMENT THIS AGREEMENT (this “Agreement”) dated for reference the 7th day of May, 2021. BETWEEN: 5th & MAIN PARTNERSHIP (the “Landlord”) AND: ZYMEWORKS INC. (the “Tenant”) WHEREAS: A.By a lease dated January 25, 2019 (the “Original Lease”), as modified and expanded by a letter agreement dated June 27, 2019 (the “Fi |
|
| August 4, 2021 |
Exhibit 99.7 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK ?[?***?]?. May 18, 2021 VIA E-MAIL GSK 980 Great West Road Brentford, Middlesex |
|
| August 4, 2021 |
Exhibit 99.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK ?[?***?]?. September 17, 2020 VIA E-MAIL BeiGene, Ltd. c/o Mourant Ozannes Corpo |
|
| August 4, 2021 |
May 16, 2021 Exhibit 10.2 Neil Josephson Zymeworks Biopharmaceuticals Inc. Dear Neil, Re: Interim Chief Medical Officer On behalf of the senior leadership team and the Board of Directors, I am pleased to confirm your position as Interim Chief Medical Officer. Your acceptance of this assignment will Include the following changes to your compensation package, effective May 16, 2021. Your base compen |
|
| August 4, 2021 |
Exhibit 99.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[…***…]”. September 17, 2020 VIA E-MAIL BeiGene, Ltd. c/o Mourant Ozannes Corpo |
|
| August 4, 2021 |
Zymeworks Reports 2021 Second Quarter Financial Results EX-99.1 2 exhibit991q22021xpressxre.htm EX-99.1 Zymeworks Reports 2021 Second Quarter Financial Results Vancouver, Canada (August 4, 2021) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2021. “The second half of 2021 is an exciting time at Zymeworks as we pr |
|
| August 4, 2021 |
EX-99.8 15 zyme-20210630xex998.htm EX-99.8 Exhibit 99.8 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[…***…]”. Confidential Execution Ver |
|
| August 4, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Comm |
|
| August 4, 2021 |
Exhibit 99.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK ?[?***?]?. CONFIDENTIAL ZYME MAY 13, 2021 SECOND AMENDMENT TO COLLABORATION AGRE |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 4, 2021 |
EX-99.4 11 zyme-20210630xex994.htm EX-99.4 Exhibit 99.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[…***…]”. April 20, 2021 VIA E-MAIL |
|
| August 4, 2021 |
Exhibit 99.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK ?[?***?]?. September 17, 2020 VIA E-MAIL BeiGene, Ltd. c/o Mourant Ozannes Corpo |
|
| August 4, 2021 |
EX-10.1 2 zyme-20210630xex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT is made and effective as of the April 29, 2019 (the “Effective Date”). BETWEEN: Dr. Neil Josephson, having a residence […***…]1. (the “Employee”) AND: ZYMEWORKS BIOPHARMACEUTIALS INC., a corporation registered in the State of Washington and having its principal place of business at 350-2400 3rd Avenue, Seatt |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Comm |
|
| August 3, 2021 |
Exhibit 99.1 Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks? Azymetric? and EFECT? Therapeutic Platforms Vancouver, Canada (August 3, 2021) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Janssen Biotech, Inc. (Janssen) dosed the |
|
| July 28, 2021 |
Exhibit 99.1 Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa? (Tucatinib) and Chemotherapy Vancouver, Canada (July 28, 2021) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the first patient has been dosed with zanidatamab in combinatio |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commi |
|
| July 9, 2021 |
As filed with the Securities and Exchange Commission on July 9, 2021 Registration No. |
|
| July 9, 2021 |
EX-4.2 2 d166021dex42.htm EX-4.2 Exhibit 4.2 Mailing Address: Location: PO Box 9431 Stn Prov Govt 2nd Floor—940 Blanshard Street Victoria BC V8W 9V3 Victoria BC www.corporateonline.gov.bc.ca 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT CAROL PREST This Notice of Articles was issued by the |
|
| July 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commis |
|
| July 8, 2021 |
Zymeworks to Present at Ladenburg Thalmann Healthcare Conference Exhibit 99.1 Zymeworks to Present at Ladenburg Thalmann Healthcare Conference Vancouver, British Columbia (July 08, 2021) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Ladenburg Thalmann Healthcare Conference on July 14, 2021 at 4:00 p.m. ET. The presentation will b |
|
| May 26, 2021 |
Zymeworks to Present at Jefferies Virtual Healthcare Conference EX-99.1 2 d162461dex991.htm EX-99.1 Exhibit 99.1 Zymeworks to Present at Jefferies Virtual Healthcare Conference Vancouver, British Columbia (May 26, 2021) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2 |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commis |
|
| May 18, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of inc |
|
| May 6, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commiss |
|
| May 6, 2021 |
Exhibit 99.2 Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting Vancouver, Canada (May 6, 2021) ? Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 5, 202 |
|
| May 6, 2021 |
Exhibit 99.1 ZYMEWORKS INC. (the ?Company?) Annual General Meeting of Shareholders May 5, 2021 REPORT OF VOTING RESULTS Section 11.3 of National Instrument 51-102 ? Continuous Disclosure Obligations Common Shares represented at the Meeting: 29,226,661 Total issued and outstanding Common Shares as at record date: 46,164,051 Percentage of issued and outstanding Common Shares represented: 63.31% Busi |
|
| May 5, 2021 |
Zymeworks Reports 2021 First Quarter Financial Results EX-99.1 2 exhibit991q12021xpressxre.htm EX-99.1 Zymeworks Reports 2021 First Quarter Financial Results Vancouver, Canada (May 5, 2021) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2021. “As we look ahead over the next 12 months, Zymeworks is focused on del |
|
| May 5, 2021 |
EX-10.1 2 zyme-20210331xex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT is made and effective as of April 1, 2020 (the “Effective Date”). BETWEEN: Mr. James Priour, having a residence at […***…]1. (the “Employee”) AND: ZYMEWORKS BIOPHARMACEUTICALS INC., a corporation registered in the State of Washington and having its principal place of business at 2100-1215 Fourth Avenue, Seat |
|
| May 5, 2021 |
EX-10.2 3 zyme-20210331xex102.htm EX-10.2 Priour, James Exhibit 10.2 March 3, 2021 Mr. James Priour Senior Vice President, Commercial Dear James, Re: Annual Compensation Review Our Compensation Review Process for the 2020 performance year is now complete. On behalf of the Zymeworks’ Board of Directors, I am pleased to confirm your promotion to the position of Chief Commercial Officer, in addition |
|
| May 5, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Zymeworks Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38068 98-1398788 (State or other jurisdiction of incorporation) (Commiss |
|
| May 5, 2021 |
Exhibit 99.1 THIRD LEASE MODIFICATION AGREEMENT THIS AGREEMENT (this ?Agreement?) dated for reference the 17 day of February, 2021, BETWEEN: 5th & MAIN PARTNERSHIP (the ?Landlord?) AND: ZYMEWORKS INC. (the ?Tenant?) WHEREAS: A.By a lease dated January 25, 2019 (the ?Original Lease?), between the Landlord and the Tenant, as modified and expanded by a letter agreement dated June 27, 2019 and by a Le |
|
| May 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
